



## TCR<sup>2</sup> Therapeutics to Present at SVB Securities Global Biopharma Conference 2023

February 8, 2023

CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- TCR<sup>2</sup> Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will present a company update at the SVB Securities Global Biopharma Conference (virtual) on Tuesday, February 14, 2023 at 1:00 PM ET.

A live webcast of the presentation will be available on the Investors page of the Company's website at [investors.tcr2.com](https://investors.tcr2.com). An archived replay will be available for at least 30 days following the presentation.

### About TCR<sup>2</sup> Therapeutics

TCR<sup>2</sup> Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC<sup>®</sup>-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR<sup>2</sup>, please visit [www.tcr2.com](https://www.tcr2.com).

### Media Contact:

Kathy Vincent  
[kathy@kathyvincent.com](mailto:kathy@kathyvincent.com)

### Investor Contact:

Eric Sullivan  
Chief Financial Officer  
[eric.sullivan@tcr2.com](mailto:eric.sullivan@tcr2.com)



Source: TCR<sup>2</sup> Therapeutics